Brief: Pharming Group Q1 Revenue Down to USD 42.5 Mln

Pharming

11/05/2023 06:26

May 11 (Reuters) - Pharming Group NV  PHAR.AS :
    * PHARMING GROUP REPORTS FINANCIAL RESULTS FOR THE FIRST
QUARTER
OF 2023
    * Q1 REVENUE FELL 9 PERCENT TO $42.5 MILLION
    * FDA APPROVAL AND COMMERCIAL LAUNCH OF JOENJA® (LENIOLISIB)
IN
U.S.
    * JOENJA® LAUNCH OFF TO STRONG START WITH 23 U.S. PATIENTS
ON PAID
THERAPY
    * REVENUES DECREASED BY 9% TO US$42.5 MILLION, COMPARED TO
Q1 OF
2022
    * CONTINUE TO ANTICIPATE LOW SINGLE DIGIT GROWTH IN ANNUAL
REVENUES FROM RUCONEST® IN 2023
    * CONTINUED SIGNIFICANT INVESTMENTS MADE IN LENIOLISIB
LAUNCH
PREPARATIONS AND ORGANIZATIONAL STRUCTURE
    * OVERALL CASH BALANCE OF US$184.8 MILLION AT END OF QUARTER

Source text for Eikon:  ID:nPn6hDlsha 
Further company coverage:  PHAR.AS 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com ; +48 58 769 66 00;))